90-day fills for chronic hepatitis B treatments increased patient adherence
Being prescribed a 90-day or a “mixed duration” supply of entecavir or tenofovir disoproxil fumarate was associated with higher fill rates among commercially insured patients with chronic hepatitis B, researchers found.“There has been a lot of important research on barriers that prevent patients with chronic hepatitis B (CHB) from receiving the care they need,” Jonathan…